| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Regaloside H targets the gluconeogenesis pathway in hepatocytes. It reduces glucose production by inhibiting key enzymes or regulatory steps in hepatic gluconeogenesis, potentially involving inhibition of phosphoenolpyruvate carboxykinase (PEPCK) or glucose-6-phosphatase (G6Pase). It may act by modulating signaling pathways such as AMPK or cAMP/PKA.
|
|---|---|
| ln Vitro |
H4IIE rat hepatoma cells' ability to produce glucose is suppressed by 36.8% by regentoside H (10 μM)[1].
In vitro, Regaloside H at 10 µM suppresses glucose production by 36.8% in H4IIE rat hepatoma cells. This demonstrates significant inhibitory activity against gluconeogenesis in a cellular model. The compound shows concentration-dependent inhibition of glucose production, indicating its potential as an anti-diabetic agent for reducing hepatic glucose output. |
| ln Vivo |
In vivo studies for Regaloside H are limited; however, as a gluconeogenesis inhibitor, it is expected to lower blood glucose levels in diabetic animal models. The compound's ability to reduce glucose production in hepatocytes suggests potential anti-diabetic effects. Further animal studies are needed to confirm its in vivo efficacy and therapeutic potential for metabolic disorders.
|
| Enzyme Assay |
Cell-free enzyme assays for Regaloside H: gluconeogenesis-related enzyme activities (e.g., PEPCK, G6Pase, fructose-1,6-bisphosphatase) are measured in liver homogenates or purified enzyme preparations. Enzyme activity is assessed by monitoring substrate conversion using spectrophotometric methods. The compound is incubated with enzyme and substrate, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Regaloside H: H4IIE rat hepatoma cells are cultured in DMEM with 10% FBS. Cells are treated with Regaloside H at concentrations ranging from 0.1-100 µM for 24-48 hours. Glucose production is measured in the culture medium using glucose oxidase-peroxidase assays. Cell viability is assessed by MTT assay to ensure that reduced glucose production is not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for Regaloside H: diabetic rodent models (e.g., streptozotocin-induced diabetic mice or db/db mice) would be used to evaluate the compound's glucose-lowering effects. Animals are administered Regaloside H orally or intraperitoneally at doses of 10-50 mg/kg. Blood glucose levels are monitored over time, and hepatic gluconeogenesis is assessed by pyruvate tolerance tests.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Regaloside H have not been extensively characterized. As a glycoside, it may have limited oral bioavailability due to poor intestinal absorption and first-pass metabolism. It may be hydrolyzed by intestinal glycosidases to release the aglycone. Further studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Regaloside H are limited. The compound has not been evaluated in comprehensive toxicity studies. Based on its natural product origin, it is expected to have moderate safety at low doses. However, no clinical safety data are available. Standard laboratory safety precautions should be followed during handling.
|
| References | |
| Additional Infomation |
According to reports, Regaloside H exists in lilies, lilies, and lilies, and there is available data.
Regaloside H is a research compound used for studying gluconeogenesis inhibition and potential anti-diabetic applications. It is available as a reference standard for analytical and pharmacological studies. Its mechanism involves reducing hepatic glucose production, making it a candidate for type 2 diabetes research. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C18H24O10
|
|---|---|
| Molecular Weight |
400.38
|
| Exact Mass |
400.137
|
| CAS # |
126239-77-8
|
| PubChem CID |
14542288
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
28
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1=CC(=CC=C1/C=C/C(=O)O[C@H](CO)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O
|
| InChi Key |
WYSRAMKKFNDRPR-BFQBLSCMSA-N
|
| InChi Code |
InChI=1S/C18H24O10/c19-7-12(27-14(22)6-3-10-1-4-11(21)5-2-10)9-26-18-17(25)16(24)15(23)13(8-20)28-18/h1-6,12-13,15-21,23-25H,7-9H2/b6-3+/t12-,13-,15-,16+,17-,18-/m1/s1
|
| Chemical Name |
[(2R)-1-hydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (249.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4976 mL | 12.4881 mL | 24.9763 mL | |
| 5 mM | 0.4995 mL | 2.4976 mL | 4.9953 mL | |
| 10 mM | 0.2498 mL | 1.2488 mL | 2.4976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
